Home/Pipeline/Lead Candidate (e.g., RNTX-101)

Lead Candidate (e.g., RNTX-101)

Alzheimer's Disease

Phase 1 / Phase 2Active (Inferred)Not Publicly Disclosed

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 1 / Phase 2

Status

Active (Inferred)

Company

Rein Therapeutics

About Rein Therapeutics

Rein Therapeutics is a US-based, public biotech company (RNTX) with a mission to develop disease-modifying therapies for neurological disorders. The company is advancing a pipeline of novel candidates through clinical development, targeting core pathways in neurodegeneration. Its strategy hinges on translating its proprietary platform into differentiated therapeutics for high-value indications, positioning it as a specialized player in the challenging neurology space.

View full company profile

Therapeutic Areas

Neurology Neurodegenerative Diseases

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	Johnson and Johnson Innovative Medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active
PMN310	ProMIS Neurosciences	Phase 1b	Active - PRECISE-AD trial fully enrolled